PUBLIC COMPANY
saveADARx Pharmaceuticals Inc
founded 2019 · 125 employees · San Diego, CA, USupdated 5mo ago
ADARx Pharmaceuticals is a clinical-stage biotechnology company developing next-generation RNA-targeted therapeutics, including siRNA, antisense, and proprietary RNA editing (EditR) platforms. Its pipeline spans genetic, cardiometabolic, complement-mediated, and central nervous system diseases, with lead programs ADX-324 (hereditary angioedema) and ADX-038 in clinical development.
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- 2026 Q3 Job Market Report: Job opportunities, layoffs show YOY improvementDuring Q3, there was a 31% year-over-year increase in job postings live on BioSpace. The number of employees affected by layoffs dropped 90%.biospace · 4d ago
- This week in charts: a big year for RNAi developersThe latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.biopharma_dive · 24d ago
- Biotech notches 31 IPOs already this year, with 4 more joining queueThe sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…biospace · 25d ago
- Alnylam bulls and bears fight it out after business-shaking guidance cutWhile Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.biospace · 27d ago
- City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipelineCity Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.biospace · 1mo ago
- City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to NasdaqCity Therapeutics has gone public with an upsized $200 million IPO, on the same day that Frazier Life Sciences listed its second biotech-focused shell company.fiercebiotech · 1mo ago
- OrbiMed’s largest-ever Asian fund contributes to $3B war chestOrbiMed has raised $3 billion to place a fresh round of bets on biotechs and life sciences companies in the U.S., Europe and Asia.fiercebiotech · 1mo ago
- TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering termsTRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push…biospace · 1mo ago
- TCGX launches $600M fund to bankroll Asian biotechsInvestment firm TCGX is expanding in Asia, raising $600 million to funnel into biotechs emerging from a burgeoning drug discovery hotspot.fiercebiotech · 1mo ago
- TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go publicEli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for a more modest $33.8 million and protein degradation biotech Lycia Therap…fiercebiotech · 1mo ago
comments(0)
5-min edit window · permanent after that